Video

Dr Rob Fields Discusses How the Proposed MSSP Changes Impact Decisions Around ACOs

Rob Fields, MD, assistant profession, family medicine and community health, Icahn School of Medicine at Mount Sinai, and senior vice president, chief medical officer, population health at Mount Sinai Health System, discusses how Mount Sinai’s accountable care organizations (ACOs) will have to adjust to the proposed CMS Medicare Shared Savings Program (MSSP) changes.

Rob Fields, MD, assistant profession, family medicine and community health, Icahn School of Medicine at Mount Sinai, and senior vice president, chief medical officer, population health at Mount Sinai Health System, discusses how Mount Sinai’s accountable care organizations (ACOs) will have to adjust to the proposed CMS Medicare Shared Savings Program (MSSP) changes.

Transcript

Mount Sinai has multiple ACOs. How do you foresee the proposed changes to MSSP potentially affecting the Track 1+ ACO or the other ACOs?

I think for Track 1+ specifically, it actually may not affect us quite as much, because we’re already culturally there in terms of taking risk and how we perceive risk and manage around it. So, I think that’s actually a little easier to get our heads around than, perhaps, our 2 Track 1, no downside risk ACOs, where the scheduling now is off. It’s now compressed in terms of where we were thinking we need to go in terms of risk and how much risk we were planning on taking. So, I think it’s affected them a little bit more.

But it certainly impacts our decisions about timing, because we are growing through a growth phase as a system now, we acquired a new system, they have their own ACO, it has changed so much of our strategy of do we combine our operations, do we combined tax IDs as we’re combining systems or not and when do we do that? All of those things have come into play as a result.

Related Videos
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo